Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

5.12 (USD) • At close February 4, 2025
Bedrijfsnaam Enanta Pharmaceuticals, Inc.
Symbool ENTA
Munteenheid USD
Prijs 5.12
Beurswaarde 109,222,400
Dividendpercentage 0%
52-weken bereik 4.71 - 17.8
Industrie Biotechnology
Sector Healthcare
CEO Dr. Jay R. Luly Ph.D.
Website https://www.enanta.com

An error occurred while fetching data.

Over Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories

Vergelijkbare Aandelen

Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc.

ACRS

2.51 USD

Kura Oncology, Inc. logo

Kura Oncology, Inc.

KURA

8.89 USD

Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc.

SANA

3.17 USD

Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc.

MIRM

50.21 USD

FibroGen, Inc. logo

FibroGen, Inc.

FGEN

0.463 USD

Cutera, Inc. logo

Cutera, Inc.

CUTR

0.438 USD

Syndax Pharmaceuticals, Inc. logo

Syndax Pharmaceuticals, Inc.

SNDX

14.41 USD

Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc.

KROS

11 USD

REGENXBIO Inc. logo

REGENXBIO Inc.

RGNX

8.43 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)